Skip to main content
. 2013 Jul 8;123(8):3231–3242. doi: 10.1172/JCI67655

Figure 3. Altered early tumor response in MerTK-deficient mice.

Figure 3

(A) Representative H&E-stained and cytokeratin-stained sections of mammary glands 4 days after injection with MMTV-PyVmT cells are shown. Boxed regions are shown at higher magnification below. Original magnification, ×100 (top row); ×600 (bottom rows). (B) Single cell mammary suspensions harvested 4 days after intramammary tumor cell injections were stained for CD11b and CD11c. Proportions of CD11b+CD11c– macrophages and CD11b+CD11c+ dendritic cells relative to total PBS-treated MerTK+/+ CD11b+CD11c+ population is shown. *P < 0.05. (C) RNA harvested 4 days after PBS, MMTV-PyVmT, or B16:F10 injection into the inguinal mammary fat pad was assessed by qPCR to detect IL-10 and IL-12p40 transcripts. (D) Serum collected 4 days after injection of PBS, MMTV-PyVmT, or B16:F10 tumor cells into the inguinal mammary fat pad was assessed by ELISA to measure IL-12p70 and IL-6. (C and D) Values shown, calculated using the (C) δδCT method or (D) serum levels, represent the average ± SD (n = 6), relative to the level detected in PBS-treated MerTK+/+ samples. *P < 0.05; **P < 0.01; ***P < 0.001. (E) Mice were inoculated with B16:F10 cells by i.p. injection. After 4 days, mice were treated with BrdU. Splenocytes harvested after 1 hour treatment with BrdU were stained with anti-BrdU and propidium iodide and assessed by flow cytometry.